+

I-STEM; Rennes, Montpellier; Sur place; EUR 60 000 - 100 000; Plein temps

Résumé du poste

An innovative firm is at the forefront of redefining cell therapies in Europe. With a strong commitment to regenerative medicine, this dynamic organization is focused on developing scalable and accessible biotherapies. By integrating cutting-edge technologies like automation and artificial intelligence, they aim to minimize errors and enhance quality control in production. The establishment of this alliance marks a pivotal moment in the industry, promising to deliver transformative solutions for severe diseases. Join a team dedicated to making a real impact on healthcare and improving patient outcomes through advanced therapies.

Prestations

Health Insurance

Flexible Working Hours

Professional Development Opportunities

Team Retreats

Qualifications

• Experience in developing scalable cell therapies is crucial.
• Knowledge of automation and AI in biomanufacturing is essential.

Responsabilités

• Lead research and development processes for cell therapies.
• Implement innovative technologies to enhance treatment effectiveness.

Connaissances

Regenerative Medicine

Cell Therapy

Automation

Artificial Intelligence

Digital Manufacturing

Formation

Master in Biotechnology

PhD in Cell Biology

Outils

Digital Twin Technology

Real-time Quality Control Systems

Description du poste

The Drug Cell :
A decisive step forward for cell therapy in Europe

The Drug Cell : A new french alliance to redefine cell therapies

The Drug Cell, a French NewCo, has been officially established marking a decisive step in the European cell therapy sector. This high-potential industrial ecosystem is designed to develop scalable and more accessible cell therapies. The Drug Cell, or TDC, brings together nine leading French biotech and innovation players: Etablissement Français du Sang (EFS), Centre d’Étude des Cellules Souches/I-Stem, Gpi France, Carroucell, EVerZom, MGA Technologies, University of Montpellier, CHU of Montpellier, and CHU of Rennes.

This milestone is reinforced by the confirmation of € 152 million in funding from the French General Secretariat for Investment, under the “France 2030” initiative . These resources will allow The Drug Cell to launch and manage the first two phases of the project: research and development processes and the First Industrial Deployment (FID). This strategic support will enable the company to initiate the first clinical trials by 2030, with an estimated time to market in 2034.

The company aims to establish itself a French and European leading player in regenerative medicine with advanced cell therapies. Its priority is to ensure access to innovative biotherapies at sustainable costs, laying the foundation for a globally competitive product. This will be achieved through the integration of cutting-edge technologies, where automation, artificial intelligence, and digital manufacturing will minimize errors, ensure real-time quality control, and enhance scalability. Meanwhile, the use of its own breakthrough technologies will strengthen the competitiveness and production autonomy of the developed solutions. Among the many innovations, the use of Digital Twin technology – virtual models that replicate cell behavior – will be implemented from the early stages. This will enable real-time monitoring and adaptation of each therapy, optimizing treatments even before patient testing.

Recently, Sergio Manzana (GPI France) was appointed President of The Drug Cell. He stated: “The establishment of The Drug Cell marks a decisive step towards Europe’s industrial autonomy in cell therapy production, with France at the heart of this revolution. We will provide new solutions for severe diseases that currently lack effective treatments, such as rare or genetic diseases. We are creating an unprecedented ecosystem that unites public and private actors, with the goal of demonstrating through real-world solutions the transformative impact of healthcare technologies on people’s lives.”